Kudos to Neuren for getting Daybue to market. Let's hope that as a breakthrough treatment it achieves the success that the Rett community deserves.
However Neuren's investment future is predominantly now in the hands of 2591. Despite the milestones achieved thus far, the situation is still (perhaps highly) speculative and as such the market is (perhaps rightly) treating us with caution. Missteps are punished severely and successes must withstand the intervals in between. That is the reality of the market.
Bring on the next 3 P2 results and hope that speculation is transformed into reality.
Need I say it - but GO NEUREN.
Share Price, page-10072
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.33 |
Change
0.510(2.71%) |
Mkt cap ! $2.433B | |||
| Open | High | Low | Value | Volume |
| $19.14 | $19.43 | $18.88 | $5.159M | 269.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6200 | $20.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.40 | 13292 | 4 |
View Market Depth
| Last trade - 15.59pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.35 |
Change
0.510 ( 2.80 %) |
||||
| Open | High | Low | Volume | ||
| $19.14 | $19.42 | $18.88 | 78348 | ||
| Last updated 15.59pm 13/06/2024 ? | |||||
| NEU (ASX) Chart |